Krabbe Disease Treatment Market Research Report- Forecast to 2022

Krabbe Disease Treatment Market Research Report- Forecast to 2022

ID: MRFR/HC/1301-HCRR | November, 2018 | Region: Global | 80 pages | Half-Cooked Research Reports

Krabbe Disease Treatment Market Information, by Types of treatments (anticonvulsant medication, physical therapy, muscle relaxer drugs, Bone Marrow Transplantation) by end users (Hospitals and Clinics, Research Centers, laboratories) - Forecast to 2022

Market Synopsis of the Market:

Market Scenario:

Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to make myelin in a human body. Globally the market for Krabbe disease is expected to grow at the rate of about XX% from 2016 to 2022.

Key Finding

  • The European market is expected to reach $XX billion by 2022.

  • Anticonvulsant medication holds the largest share of XX% of the Krabbe disease treatment market.

  • North America holds the largest market share of XX% of Krabbe disease treatment and is expected to reach $XX billion by the end of forecast period.

  • Asia Pacific is expected to be the fastest growing market at a CAGR of XX%

Study objectives of the Market:

  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Krabbe Disease Treatment market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to the main geography and its countries - North America, Europe, Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by types of treatment, by end users, and its sub-segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the market.

Krabbe Disease Treatment market, by types of treatment

Krabbe Disease Treatment market, by types of treatment

Key Players for the Market:                                                                            

Some of the key players in this market are: Abbott Laboratories, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Johnson & Johnson, Novartis AG, Pfizer, Sanofi-Aventis SA, Shire, and UCB Pharmaceuticals.


Krabbe Disease treatment market has been segmented on the basis of types of treatments which comprises of anticonvulsant medication, physical therapy, muscle relaxer drugs, bone marrow transplantation and others. On the basis of end users the market is segmented into hospitals and clinics, research centers, laboratories and others

Regional Analysis of the Market:                                                                              

Globally North America is the largest market for Krabbe disease treatment. Europe is the second-largest market and Asia Pacific is expected to grow at a fastest rate.

Intended Audience

  • Krabbe Disease treatment equipment manufacturers & Suppliers

  • Krabbe Disease Drug manufacturers & Suppliers

  • Pharmaceutical and biotechnology companies

  • Hospitals and laboratories

  • Academic research institutes

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

5 Market Factor Analysis

5.1 Value/Supply Chain Analysis

5.2 Porter's 5 Forces Analysis

6 Global Krabbe Disease Treatment Market, By Treatment Types (USD Million)

6.1 Introduction

6.2 Historical Market Growth

6.3 Market Size By Treatment Types

6.3.1 anticonvulsant medication

6.3.2 physical therapy

6.3.3 muscle relaxer drugs

6.3.4 bone marrow transplantation

6.3.5 hematopoietic stem cell transplant (HSCT)

6.3.6 Others

7 Global Krabbe Disease Treatment Market, By End Users (USD Million)

7.1 Introduction

7.2 Historical Market Growth

7.3 Market Size By End Users

7.3.1 Hospitals and clinics

7.3.2 research centers

7.3.3 laboratories

7.3.4 Others

8 Global Krabbe Disease Treatment Market, By Region

8.1 Introduction

8.2 Incidence of Krabbe Disease Treatment Market By Region

8.3 Market Size By Region

8.3.1 North America US Canada

8.3.2 Europe Western Europe Germany France UK Italy Spain Restof Western Europe

8.3.3 Asia-Pacific Asia Japan China India Republic of Korea Rest of Asia Pacific

8.3.4 Middle East & Africa

9 Company Landscape

9.1 Introduction: Key Players

9.2 Market Share Analysis

9.3 Key Development & Strategies

10 Company Profiles

10.1 Abbott Laboratories

10.1.1 Company Overview

10.1.2 Product/Business Segment Overview

10.1.3 Financial Updates

10.1.4 Key Developments

10.2 Teva Pharmaceutical Industries Ltd

10.2.1 Company Overview

10.2.2 Product/Business Segment Overview

10.2.3 Financial Updates

10.2.4 Key Developments

10.3 GlaxoSmithKline

10.3.1 Company Overview

10.3.2 Product/Business Segment Overview

10.3.3 Financial Updates

10.3.4 Key Developments

10.4 Johnson & Johnson

10.4.1 Company Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financial Updates

10.4.4 Key Developments

10.5 Novartis AG

10.5.1 Company Overview

10.5.2 Product/Business Segment Overview

10.5.3 Financial Updates

10.5.4 Key Developments

10.6 Pfizer

10.6.1 Company Overview

10.6.2 Product/Business Segment Overview

10.6.3 Financial Updates

10.6.4 Key Developments

10.7 Sanofi-Aventis SA

10.7.1 Company Overview

10.7.2 Product/Business Segment Overview

10.7.3 Financial Updates

10.7.4 Key Developments

10.8 Shire

10.8.1 Company Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financial Updates

10.8.4 Key Developments

10.8 UCB Pharmaceuticals

10.8.1 Company Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financial Updates

10.8.4 Key Developments

10.9 Others

11 Conclusion

12 Appendix